Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders Growth (3y) (2021 - 2026)
Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 80.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.10% |
| Mar 31, 2026 | 136.54% |
| Dec 31, 2025 | 137.76% |
| Sep 30, 2025 | 106.01% |
| Jun 30, 2025 | 31.90% |
| Mar 31, 2025 | 137.63% |
| Dec 31, 2024 | -48.16% |
| Sep 30, 2024 | 68.39% |
| Jun 30, 2024 | 4.93% |
| Mar 31, 2024 | -142.04% |
| Dec 31, 2023 | -219.07% |
| Sep 30, 2023 | 45.48% |
| Jun 30, 2023 | 44.12% |
| Mar 31, 2023 | -27.25% |
| Dec 31, 2022 | 48.72% |
| Sep 30, 2022 | 78.35% |
| Jun 30, 2022 | -92.63% |
| Mar 31, 2022 | 64.42% |
| Dec 31, 2021 | 10.07% |
| Sep 30, 2021 | -37.67% |